HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up

Executive Summary

Attorneys are warning CBD product marketers to be on guard for litigation challenging the authenticity of their claims, the safety of their products and other aspects of their businesses. So far, suits of this nature have been limited in the US, but the few known cases could be harbingers of a larger wave to come.

You may also be interested in...

Amyris Making Headway In Fermentation-Derived Cannabinoids; CBD Could Hit Market In Early 2020

Synthetic biology firm Amyris has shipped to partner Lavvan its first cannabinoid produced via genetically engineered yeast. While Amyris’ announcement does not identify the specific cannabinoid, Lavvan leadership indicated in March 2019 that fermentation-derived CBD would be first to market, representing potential purity and value benefits compared with CBD extracted from the cannabis plant.

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

‘Free Of' Claims Can Cost: Complaints Mounting From 'Consumer Perception'

Plaintiffs’ bar seeks ‘free of’ claim inaccuracies on supplements, including claims that stray from federal or industry standards, says attorney Kristi Wolff in CRN webinar. Common pitfalls include “100% gluten free,” “no trans fat” and “THC-free.”

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts